Search Results
Results found for "Thue Schwartz"
Posts (2)
- Chemokine receptor-targeted drug discovery: progress and challenges
development of biased ligands, which promote the engagement of the receptor with a certain effector, thus therapeutic applications are situated in the area of chronic inflammatory disease (Proudfoot, Power, and Schwarz
- A robust and Efficient FRET-Based Assay for Cannabinoid Receptor Ligands Discovery.
higher potency in the CB1R. [9,10] 1.2 Novel fluorescent strategies for CBR binding affinity assays Thus narrow bands and high stokes shift, which prevent cross-excitation and cross-emission phenomena.[18] Thus GPCRs are not suitable for antibody use due to steric hindrance and reverse binding, thus, other strategies Thus, the same set of compounds used for CB1R competition assays was used in CB2R. Table 3. D.; Irizarry, L.; Trecki, J.; Schwartz, M.; Gerona, R.
Other Pages (5)
- Dr. Claudia Stäubert | Dr. GPCR Ecosystem
fascinated by G protein-coupled receptors (GPCRs) due to a stay as a scholarship student in the lab of Thue Schwartz (Copenhagen, Denmark).
- Dr. Maria Waldhoer | Dr. GPCR Ecosystem
GPCRs led Maria to Thue W. Schwartz’s lab in Copenhagen where she completed her postdoctoral training.
- Exploring Career Paths in GPCR Research with Dr. Jacek Mokrosiński | Dr. GPCR Ecosystem
then moved to Denmark, where he trained at the University of Copenhagen under supervision of Professor Thue Schwartz, and worked closely with Dr Birgitte Holst studying structural and mechanistic properties of also shared their appreciation for documentaries showcasing manufacturing processes and the value of true
Events (1)
- Development of GPCR Ligands as Therapeutic DrugsTickets: $0.00March 20, 2025 | 2:00 PM





